Highlights
In 2023, VHIR's Board of Trustees (Patronato) approved the constitution and/or participation to two companies participated by VHIR.
Income generated by the activities of the Innovation Unit (royalties and ufront payments from licenses, OHs from collaboration agreements and competitive grants, etc.)
Research collaborations between research groups at VHIR and companies, involving an innovation project.
Ratio of licensed patents to all applied patents
Total funding of our companies, public & private, competitive & non competitive
Evolution of Income for innovation activity
Evolution of Income for innovation activity. The activities are described in the section: "Revenue collected by type of innovation activities"
Spin-off’s approved in 2023
ARTIS
ENDOLIPID DERMA
In 2023, VHIR's Board of Trustees (Patronato) approved VHIR's participation in 2 companies.
Patents 2023
Patent families applied in 2023 (Patent families are the set of patent applications that derive from a first priority patent application)
Utility Model Families in 2023 (Families are the set of applications that derive from a first Utility Model)
National patent applications arising from an international PCT application.
"Families" of Patents for which an exploitation agreement has been signed with a company (in this case called a licensee)
In total, Patents of VHIR:
All patent families applied to 2023 inclusive
Impact & other resources captured and confirmed during 2023
Revenue from SpinOffs in which the VHIR participates
Number of people employed by companies where VHIR is one of the shareholders.
Total Fair Value, at 2023 closing, of the whole historic portfolio of companies where VHIR is one of the shareholders (including exits and write-offs.
Direct or contribution. Competitive calls where our portfolio companies participate, and usually VHIR is also involved
